ArticleFrontiers in oncology2026
Leptomeningeal metastasis from colon cancer: a case report and review of literature.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Leptomeningeal metastasis from colorectal cancer (LM-CRC) is a rare condition characterized by poor outcomes and no established standard of care. Case description: We report a 60-year-old female patient who presented with constipation and abdominal pain. Eight months prior, she had been diagnosed with poorly differentiated adenocarcinoma of the sigmoid colon with focal signet-ring cell features, proficient mismatch repair, and a KRAS mutation. She had received treatment with FOLFOX/FOLFIRI ± bevacizumab. Five days before admission, she developed headache and vomiting. Contrast-enhanced brain MRI suggested leptomeningeal metastasis, which was confirmed by lumbar puncture cytology. Owing to progressive symptom deterioration, the patient did not receive any antitumor therapy timely and died two weeks after symptom onset. In this review, we summarize 29 cases of LM-CRC, aiming to characterize the pathology, symptoms, diagnosis, and survival data of LM-CRC in order to enhance clinicians' awareness of this rare disease. Conclusion: The incidence of LM-CRC is low and the prognosis is extremely poor; active anti-tumor therapy may prolong patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.